2011 | Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers | 문영철 | Meeting Abstract |
2016 | Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients | 문영철 | Article |
2019 | Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis | 문영철 | Article |
2015 | Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma | 문영철 | Article |
2019 | Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System | 문영철 | Article |
2019 | Degranulated Eosinophils Contain More Fine Nerve Fibers in the Duodenal Mucosa of Patients With Functional Dyspepsia | 정혜경; 문영철; 박상희 | Article |
2021 | Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT | 문영철 | Article |
2023 | Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study | 문영철 | Article |
2016 | Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study | 문영철 | Article |
2015 | Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial | 문영철 | Meeting Abstract |
2008 | Final Report of "Korean Multicenter AML-2000 Trial": Intention to Treat Analysis Based on Cytogenctics Risk | 문영철 | Meeting Abstract |
2018 | Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients | 문영철 | Article |
2011 | Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation | 허정원 | Meeting Abstract |
2007 | Hematopoietic stem cells mobilization by G-CSF and LTB4 was significantly suppressed by an oxygen radical scavenger or an inhibitor of NADPH oxidase | 성주명; 유은선; 이경은; 문영철 | Meeting Abstract |
2012 | Hepatitis B Virus Reactivation in Chronic Myeloid Leukemia Treated with Various Tyrosine Kinase Inhibitors: Multicenter, Retrospective Study | 문영철 | Meeting Abstract |
2016 | Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study | 문영철 | Article |
2016 | Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study | 문영철 | Article |
2009 | Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). | 문영철 | Meeting Abstract |
2019 | Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy | 문영철 | Article |
2009 | Induction Therapy with "3+7" Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups | 성주명; 문영철 | Meeting Abstract |
2010 | Intensified 1st Cycle Rituximab (R) Plus 8(th) Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20(+) Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis. | 문영철 | Meeting Abstract |
2023 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 문영철 | Article |
2020 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis | 문영철 | Article |
2020 | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) | 문영철 | Article |
2023 | Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea | 문영철 | Article |
2022 | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia | 성주명; 문영철; 김대영; 박영훈 | Article |
2019 | Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial | 문영철 | Article |
2011 | Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation | 문영철 | Meeting Abstract |
2011 | Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study | 문영철 | Meeting Abstract |
2015 | Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | 문영철 | Article |